Adlai Nortye Group Ltd.

Adlai Nortye Group Ltd. की हमारे पास उपलब्ध सबसे नई तिमाही

कंपनी की अपनी 6-K रिपोर्ट से।

प्रबंधन ने क्या कहा

“We continue to execute well across our pipeline, with initial clinical data on track for both of our pan-RAS(ON) inhibitor-based assets in 2027,”

विज्ञप्ति से हूबहू उद्धृत, और तभी दिखाया गया जब रिपोर्ट उसे किसी नामित व्यक्ति से जोड़ती है।

Adlai Nortye Group Ltd. क्या करती है

Adlai Nortye is a global clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies. The global infrastructure supports the efficient execution of our robust pipeline of drug candidates covering two key therapeutic areas: 1) Precision RAS pathway targeted therapies: including the oral pan-RAS(ON) inhibitor AN9025, and the CEACAM5-targeting ADC AN4035 engineered from the Company’s proprietary RASiCA™ (RAS Inhibitor Conjugated Antibody) platform, which efficiently delivers a potent pan-RAS(ON) inhibitor to the tumor site. 2) Next-generation PD-1/L1 pathway modulating immunotherapies: including AN8025, a multi-functional fusion protein that simultaneously modulates T cells and antigen-presenting cells. 4

कंपनी का अपना विवरण, जैसा विज्ञप्ति के अंत में दिया गया है।